Equities Analysts Set Expectations for TG Therapeutics, Inc.’s FY2025 Earnings (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities researchers at HC Wainwright cut their FY2025 earnings estimates for TG Therapeutics in a research note issued to investors on Thursday, May 2nd. HC Wainwright analyst E. White now expects that the biopharmaceutical company will earn $0.11 per share for the year, down from their previous estimate of $0.19. HC Wainwright currently has a “Buy” rating and a $49.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for TG Therapeutics’ FY2026 earnings at $0.49 EPS.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). TG Therapeutics had a net margin of 14.24% and a return on equity of 33.79%. The company had revenue of $63.47 million for the quarter, compared to analysts’ expectations of $54.60 million. During the same quarter last year, the business posted ($0.28) EPS. The business’s quarterly revenue was up 713.5% compared to the same quarter last year.

Several other equities analysts have also commented on the company. The Goldman Sachs Group increased their price objective on TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Thursday, February 29th. B. Riley boosted their price objective on shares of TG Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Monday, February 5th. StockNews.com cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 24th. LADENBURG THALM/SH SH lifted their target price on shares of TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $25.00 target price on shares of TG Therapeutics in a research report on Thursday, April 18th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.83.

TG Therapeutics Trading Down 1.4 %

NASDAQ TGTX opened at $16.19 on Monday. The company has a quick ratio of 5.18, a current ratio of 5.92 and a debt-to-equity ratio of 0.62. The stock’s 50-day simple moving average is $15.25 and its two-hundred day simple moving average is $14.46. TG Therapeutics has a twelve month low of $6.46 and a twelve month high of $35.67. The company has a market capitalization of $2.50 billion, a price-to-earnings ratio of 70.39 and a beta of 2.33.

Insiders Place Their Bets

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of the firm’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the sale, the director now owns 215,229 shares of the company’s stock, valued at approximately $3,437,207.13. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

A number of large investors have recently added to or reduced their stakes in TGTX. Commonwealth Equity Services LLC grew its holdings in TG Therapeutics by 19.6% in the 3rd quarter. Commonwealth Equity Services LLC now owns 182,400 shares of the biopharmaceutical company’s stock worth $1,525,000 after acquiring an additional 29,878 shares during the last quarter. Raymond James & Associates boosted its stake in shares of TG Therapeutics by 2.9% during the 3rd quarter. Raymond James & Associates now owns 150,190 shares of the biopharmaceutical company’s stock valued at $1,256,000 after purchasing an additional 4,176 shares in the last quarter. Stratos Wealth Partners LTD. bought a new stake in shares of TG Therapeutics during the 3rd quarter valued at about $87,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of TG Therapeutics by 11.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,412 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 2,805 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of TG Therapeutics by 25.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 85,580 shares of the biopharmaceutical company’s stock valued at $715,000 after purchasing an additional 17,207 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.